Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03938649Phase 2Active Not Recruiting

SRAM study_Postate Cancer

Role: lead

NCT03419481Phase 2Active Not Recruiting

Pembrolizumab in Hepatocellular Carcinoma

Role: lead

NCT03997435Phase 2Active Not Recruiting

FOLFOXIRI With or Without Intensification for Rectal Cancer

Role: lead

NCT03079219Phase 3Completed

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients

Role: lead

All 4 trials loaded